Thursday, 5 December 2024
  
Login

Australia's most trusted
source of pharma news

Thursday, 05 December 2024
News

Blockbusters go head-to-head

Posted 9 October 2024 AM

Johnson & Johnson is trying to boost sales of its prostate cancer drug Erlyand against its main rival, Astellas' Xtandi, with a head-to-head comparison of real-world data.

An abstract presented at the 6th European Congress of Oncology Pharmacy (ECOP) in Portugal earlier this month showed the results of a study of 3,719 people with metastatic castration sensitive prostate cancer (mCSPC) who had not taken an androgen-receptor pathway inhibitor (ARPIs), as they started on either Erlyand or Xtandi.

To see the whole article, please login

Popular

Disruption coming to Med Affairs
$56M drug hit with first generic
Four PBS listings wrap up 2024
Biosim rushes for $72M market
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2024 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home